Welichem Obtains Approval for Phase IIa Clinical Trial on Eczema
The Company will initiate its Phase IIa Clinical Trial of WBI-1001 as a topical cream application against atopic dermatitis in the coming months. Atopic dermatitis is normally treated topically with corticosteroids or other immune-suppressors, and these treatments often result in adverse effects after long-term use. WBI-1001 has been developed as a more effective and tolerable topical treatment of this chronic disease.
The Company has completed a Phase I Clinical Trial of this drug candidate on psoriasis, and the clinical data on its safety and efficacy in the Trial should be available by the end of April this year. A Phase II study to confirm and explore its safety and efficacy on psoriasis is planned for mid-2008. Meantime, the Company continues on its rigorous research and development schedule.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.